Investors in Service

We are a VC built and backed by entrepreneurs. We invest in sustainable change. Our mission: To find, fund, and power European innovators who are shaping the future with solutions that meet humanity's needs without compromising the planet. Driven by our experience, knowledge, and networks, we strategize, iterate, build, and win. Our results speak volumes. Over the past 10 years, we have helped power over 90 companies, completing 27 successful exits. We make swift, intuitive decisions, trusting your ideas and the ability to drive market disruption with pioneering solutions for a sustainable future.

Negma Group is a leading innovative investment company focused on supporting growth and capturing value through a multi-strategy approach. With our debt and equity financing solutions, venture capital efforts, private equity, and quantitative trading strategies, we present impactful and sustainable opportunities to SMEs, startups, and investors globally. Built upon a structure that fosters and enables creative talent, we employ a team of innovative individuals who work collaboratively to bring forth forward-thinking data-driven solutions. As an agile and flexible market player, we repeatedly prove ourselves as a valuable partner to those seeking to grow, solve challenges, and capitalize on unique opportunities.

14Peaks is an early-stage investor in B2B SaaS companies in the fintech and future of work verticals, with a geographic focus on Europe and the US. 14Peaks initially partners with founders from pre-seed to Series A and provides on-going support throughout their growth journey via capital, operational involvement, network access and strategic advice. Partner with us:

OneRagtime has assembled a distinguished team blending entrepreneurial, corporate, M&A, and Private Equity expertise. As a venture capital firm, OneRagtime focuses on investing in innovative startups across various sectors. They provide not only financial support but also strategic guidance and operational expertise to help startups scale and succeed. OneRagtime's approach combines rigorous investment analysis with hands-on support, aiming to drive growth and create lasting value for their portfolio companies. For more information about their investment criteria and portfolio, visiting their official website would provide comprehensive insights

LEVA, the tech stack for the venture capital industry. We offer a full range product suite to launch and run your syndicate easily from your laptop. We are your partner for Angel Syndicates Deal-by-Deal Funds Rolling Syndicates Co-Investment Vehicles Club Deals. Move Capital Without Barriers – Transforming Investment Syndication for a Seamless Future.

Ace Capital Partners is a private portfolio investment management company specializing in strategic sectors. With a focus on creating long-term value, Ace Capital Partners leverages its expertise to manage investments across a diverse range of industries. Their commitment to excellence and strategic insight positions them as a trusted partner for businesses seeking sustainable growth and development.

We at RGREEN INVEST are an independent, mission-driven investment management company based in Paris, founded in 2013. Our proven track record lies in investing in and financing infrastructure projects that drive our energy transition and mitigate climate change. With over 40 experienced professionals spanning fund management, investment banking, and renewable energy expertise, our team is among the most comprehensive in Europe. Sustainability is at the core of our investment philosophy, and we integrate robust ESG principles into our investment criteria. How can our expertise in sustainable infrastructure investments support your goals?

Zühlke is a global innovation partner. We turn big opportunities into working solutions that deliver ongoing value. For people, planet, and profit. A holistic growth partner to our clients, we close the gaps between strategic ambition, tech implementation, and operational excellence, helping you thrive in a business environment that's fluid, data-led, and collaborative. Together with clients and partners, our multidisciplinary teams deliver innovation and transformation initiatives in complex and regulated industries and ecosystems. Founded in Switzerland, Zühlke is a global team of 1,900 colleagues, with 17 locations in Europe and Asia.

For over forty years, we have been providing capital support to startups, SMEs, and mid-sized companies, enabling them to grow, innovate, and transform. As a subsidiary of Crédit Mutuel Alliance Fédérale, France's leading "mission-based bank," we believe in giving entrepreneurs the necessary time to achieve their vision. Alongside them, we invest our own funds (€4 billion), which provides us with the flexibility and autonomy to support them over the long term. Each of the 350 companies we support is unique in terms of size, sector, maturity, project, and culture.

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to develop tomorrow’s standard of care to cure cancer & infectious diseases and improve patient quality of life.

At AFI Ventures, we are committed to supporting the most promising seed and pre-seed impact entrepreneurs. From climate action to promoting healthy living, we partner with every visionary who shares our ambition for deep, scalable impact. We invest up to €500k in 1 to 2 companies every month, empowering these entrepreneurs to achieve their goals. AFI Ventures serves as the seed fund of Alliance for Impact, Europe's leading impact launchpad. How can our support help drive your impactful vision forward?

We invest in innovative private early- to mid-stage human Life Science companies that address important medical needs with novel technologies or products backed by compelling science and with differentiated advantages over current treatment options. Our focus is on Switzerland and surrounding EU countries Germany, Austria, France, Italy and Benelux. We mostly invest in drug development and, to a lesser degree, in diagnostics and medical technology. The amount we aim to invest over the life time of our portfolio companies is up to CHF 10 million.